RSD

We propose to establish a Centre of Excellence in Digital Health and Personalised Medicine (CLINNOVA), addressing future medical and societal needs. A prerequisite for personalised medicine is the establishment of clinical research in Luxembourg, the current weakness that we would like to overcome with the programme. The Centre will build on the previous investments into fundamental biomedical research and link to the hospitals in Luxembourg to ensure that innovation from the bench will reach the clinic and patient care. The Centre will fully incorporate personalised medicine approaches integrating medical history from eHealth records with newly generated molecular and phenotypic data as well as environmental and/or health data from mobile devices. Teaming up with the Center for Innovativ Medicinsk Teknologi, Region Syddanmark (CIMT-RSD) and the Nationale Centrum für Tumorerkrankungen, Deutsches Krebsforschungszentrum (NCT-DKFZ) will allow us to benefit from the immense experience and world-leadership has in setting up modern eHealth infrastructures and translational cancer research. We will focus on areas where there is both existing excellence in pre-clinical research and an important clinical unmet need, namely the disease areas of cancer and neurodegenerative diseases with the transversal axis immunology as important element in both disease areas. Environmental, nutritional and social influences interpreted together with the medical history of patients and molecular diagnostic information will be key to gain an understanding of the diseases for the individual person. A strong ICT component will be a major success factor: data integration and interpretation are needed to derive computational models and predictions on disease development. The Centre will combine all aspects of technological innovation with clinical care and bring innovations to patients and doctors serving as an attractor for companies and further develop the local ecosystem.

Millions of Europeans undergo optical colonoscopy (OC) every year. OC may be associated with discomfort, complications and sick-days, which affect acceptability, and constitutes a heavy burden on European hospital capacities. Colon capsule endoscopy (CCE) is a new technology, which has the potential to replace 50 ? 65 % of all OCs. CCE is preferred by patients, has a lower complication rate and can be performed out of hospital. CCE holds great potential for both patients and hospitals. However, the diagnostic process of CCE includes a time-consuming manual reading done by trained personnel and is expensive and prone to human error. For CCE to be a viable alternative to OC these challenges need to be addressed. Thus, our goal is to create a complete and validated AI-assisted pathway that improves CCE diagnostics making the technology clinically viable for the good of patients, health care systems and society. We have already completed development of several AI algorithms (AIA) for CCE diagnostics, and more will be completed within 1 ?2 years. The AICE concept will focus on: 1) completing development of the remaining AIAs, 2) external validation the all AIAs, 3) creating a clinical support system for data handling, storage and transmission, 4) developing a diagnostic pathway that considers quality, efficiency, patient preferences, ethics and economy 5) promotes the integration of AICE solutions into clinical practice via guidelines and upscaling adjustments. To achieve these goals, AICE will use an unprecedented large and diverse collection of existing patient data from nation-wide clinical studies, and will include extensive initiatives in the fields of ethics, communication and patient engagement. To ensure the right competences are present, AICE brings together clinical researchers, epidemiologists, data scientists, digital health experts, health economists, ethics researchers, SMEs, communication experts and experts in regulatory affairs.